

This PDF is a selection from a published volume from the National Bureau of Economic Research

Volume Title: Insights in the Economics of Aging

Volume Author/Editor: David A. Wise, editor

Volume Publisher: University of Chicago Press

Volume ISBNs: 0-226-42667-X; 978-0-226-42667-9 (cloth);
978-0-226-42670-9 (e-ISBN)

Volume URL: <http://www.nber.org/books/wise-21>

Conference Date: April 30-May 2, 2015

Publication Date: March 2017

Chapter Title: Comment on "Understanding the Improvement in Disability-Free Life Expectancy in the U.S. Elderly Population"

Chapter Author(s): Jonathan Skinner

Chapter URL: <http://www.nber.org/chapters/c13632>

Chapter pages in book: (p. 201 – 204)

- Owsley, C., G. McGwin, K. Scilley, G. C. Meek, D. Seker, and A. Dyer. 2007. "Impact of Cataract Surgery on Health-Related Quality of Life in Nursing Home Residents." *British Journal of Ophthalmology* 91 (10): 1359–63.
- Rosen, A. B., D. M. Cutler, D. Norton, H. M. Hu, and S. Vijan. 2007. "The Value of Coronary Heart Disease Care for the Elderly: 1987–2002." *Health Affairs* 26 (1): 111–23.
- Salomon, J., H. Wang, M. Freeman, T. Vos, A. Flaxman, A. Lopez, and C. J. L. Murray. 2012. "Healthy Life Expectancy for 187 Countries, 1990–2010: A Systematic Analysis for the Global Burden Disease Study 2010." *Lancet* 380 (9859): 2144–62.
- Schoeni, R. F., V. A. Freedman, and L. G. Martin. 2008. "Why is Late-Life Disability Declining?" *Milbank Quarterly* 86 (1): 47–87.
- Schoeni, R. F., V. A. Freedman, and R. B. Wallace. 2001. "Persistent, Consistent, Widespread, and Robust? Another Look at Recent Trends in Old-Age Disability." *Journal of Gerontology: Social Sciences* 56B:S206–18.
- Schoeni, R., L. Martin, P. Andreski, and V. Freedman. 2005. "Persistent and Growing Socioeconomic Disparities in Disability among the Elderly: 1982–2002." *American Journal of Public Health* 95 (11): 2065–70.
- Steinberg, E. P., J. M. Tielsch, O. D. Schein, J. C. Javitt, P. Sharkey, S. D. Cassard, M. W. Legro, et al. 1994. "National Study of Cataract Surgery Outcomes: Variation in 4-Month Postoperative Outcomes as Reflected in Multiple Outcome Measures." *Ophthalmology* 101 (6): 1131–40.
- Stewart, S. T., D. M. Cutler, and A. B. Rosen. 2009. "Forecasting the Effects of Obesity and Smoking on US Life Expectancy." *New England Journal of Medicine* 361:2252–60.
- Wang, H., L. Dwyer-Lindgren, K. Lofgren, J. K. Rajaratnam, A. Rector, C. Levitz, A. Lopez, and C. Murray. 2012. "Age-Specific and Sex-Specific Mortality in 187 Countries, 1970–2010: A Systematic Analysis for the Global Burden of Disease Study 2010." *Lancet* 380 (9859): 2071–94.
- Weisfeldt, M. L., and J. Z. Zieman. 2007. "Advances in the Prevention and Treatment of Cardiovascular Disease." *Health Affairs* 26 (1): 25–37.

Comment Jonathan Skinner

The chapter by Chernew, Cutler, Ghosh, and Landrum is an ambitious one that covers considerable ground, ranging from updated measures of disability compression in the United States to the key question of how much the diffusion of health care technology has contributed to improving health outcomes. First, the authors have revisited the questions posed in Cutler, Ghosh, and Landrum (2014) to test whether the decline in disability (and increase in disability-free days) has continued through 2008; the reassuring answer is yes. But they go beyond this question to dig in more as to the

Jonathan Skinner is the James O. Freedman Presidential Professor of Economics at Dartmouth College, professor of community and family medicine at the Dartmouth Institute for Health Policy and Clinical Practice, and a research associate of the National Bureau of Economic Research.

For acknowledgments, sources of research support, and disclosure of the author's material financial relationships, if any, please see <http://www.nber.org/chapters/c13632.ack>.

causes of this continued decline: Which medical conditions have made the greatest contribution to the rise in disability-free survival, and more importantly, how much of the disease-specific declines in morbidity and mortality can be attributed to the diffusion of medical innovations such as statins or aspirin? These are great questions, and the authors have done an excellent job of addressing them using a variety of data from the demography and clinical literatures.

In my comments, I have no quarrel with the central conclusion of the chapter, but instead focus on three separate issues raised at different points in the chapter. The first is an intriguing pattern that the authors uncover regarding trends in disability prior to death. While the trend for ADL/IADL measures in the two to three years prior to death exhibited a steady decline, the fraction of people with a disability has remained stubbornly fixed at roughly four-fifths between 1991 and 2009 for those in the last year of life (their table 5.5). This might appear to be puzzling; generally, we might expect disability rates to be declining across the life cycle. But perhaps this is not so puzzling after all: people still have to die of something, and it would be surprising to find a rise in (e.g.) the fraction of sudden cardiac arrest or accidental deaths—more common causes of death among the nondisabled. Still, the empirical patterns uncovered by Chernew et al. suggest a slightly more nuanced view of disability.

For example, suppose disability arises from two general causes. The first is associated with medical factors that are not immediately life threatening, such as diabetes, depression, stable angina, or arthritis, where lifestyle changes and medical innovations might be most effective in reducing both prevalence of the disease, and ensuring that the disease is less likely to result in disability. It is these kinds of disability that we observe most often among those in the second or third year prior to death. The second type of disability arises from serious medical conditions associated with an elevated likelihood of mortality. For example, Class IV congestive heart failure (CHF) has as much as a 50 percent risk of one-year mortality (Ahmed, Aronow, and Fleg 2006), as well as a poor quality of life associated with it, and so we might be expected to find more of these CHF patients in the (unfortunate) group within one year of death. Thus moving from the second or third year prior to death into those just prior to death may represent a fundamental shift in the type of disability, with the second type far less likely to exhibit secular improvement.

Second, the authors show a substantial improvement in vision during this period, one that seems difficult to explain solely through the increase in cataract surgery. The authors have certainly done their best to solve this puzzle, with a careful read of the clinical literature and clever regression analysis. I do not have much to add to their inquiries, except to suggest that the improvement in vision may be associated with other non-cataract-related

improvements in health. For example, high blood pressure is a risk factor for vision impairment, so improved cardiovascular health will reduce vision impairment as well (van Leeuwen et al. 2003). Even among diabetics, whose population is on the rise, there has been a growth in monitoring and control, with eye examinations for diabetic patients the standard of care during the past decade. Thus the remarkable decline in vision impairment may be a dividend arising from other sources of health improvement.

Third, the authors have provided further understanding of the fundamental causes for the increase in disability-free life years. Rather than estimate treatment effects from their data, they correctly turned to the comprehensive IMPACT study (Ford et al. 2007) that uses evidence from randomized trials on drugs or cardiovascular treatments to impute how the diffusion of medical treatments (and pharmaceutical use) might have affected patient health. The authors perform this accounting exercise for cardiovascular disease, and find that roughly half of the improvement in disability-free years arises from medical treatments.

They are most likely right, but I would still argue that one must be careful in translating estimates of effectiveness from randomized trials to actual outcomes in the larger community. This was shown first in an earlier study by Wennberg et al. (1998) who compared the mortality rate for carotid endarterectomy reported in the randomized clinical trial (RCT) (e.g., 0.6 percent) with actual mortality in community-based hospitals, which was as much as 2.5 percent depending on the volume of surgical procedures. The differences in outcomes arise because the institutions in the RCT were so selective in choosing appropriate patients for the trials, and because the overall quality of the institutions that performed RCTs—typically academic medical centers—were higher than average community-based hospitals (Wennberg et al. 1998).

While Chernew et al. do not use estimates of carotid endarterectomies in their own analysis, they do use estimates of benefits arising from the increase in (e.g.) statin and estimated aspirin use, so similar issues could arise for their estimates. For example, one recent study from Finland showed substantially lower marginal health effects of statin use once one accounted for the poor adherence with the drug regimen observed in the community (Aarnio et al. 2015). Another study effects of aspirin use found evidence of its impact on lowering the incidence of cancer, but suggested that the “use of aspirin in the general population does not have a major impact on cardiovascular mortality.” (Cuzik et al. 2015). This does not detract from the view that advances in treatment had an impact on health outcomes, but it does suggest some caution in interpreting estimates from randomized trials as applying to treatments performed in the general population.

With this concern set aside, one can only hope that this team of researchers will return to the question of why disability rates continue to fall among

those not receiving new medical or pharmaceutical treatments in an environment of stagnating health care spending. It is an important question, and surely one of the few reassuring trends that we see in US health care.

References

- Aarnio, Emma, Maarit J. Korhonenemail, Risto Huupponenemail, and Janne Martikainenemail. 2015. "Cost-Effectiveness of Statin Treatment for Primary Prevention in Conditions of Real-World Adherence—Estimates from the Finnish Prescription Register." *Atherosclerosis* 239 (1): 240–47.
- Ahmed Ali, Wilbert S. Aronow, and Jerome L Fleg. 2006. "Higher New York Heart Association Classes and Increased Mortality and Hospitalization in Heart Failure Patients with Preserved Left Ventricular Function." *American Heart Journal* 151 (2): 444–50.
- Cutler, D. M., K. Ghosh, and M. Landrum. 2014. "Evidence for Significant Compression of Morbidity in the Elderly US Population." In *Discoveries in the Economics of Aging*, edited by David A. Wise, 21–50. Chicago: University of Chicago Press.
- Cutler, D. M., M. Landrum, and K. Stewart. 2008. "Intensive Medical Care and Cardiovascular Disease Disability Reductions." In *Health at Older Ages: The Causes and Consequences of Declining Disability among the Elderly*, edited by David M. Cutler and David A. Wise. Chicago: University of Chicago.
- Cuzick, J., M. A. Thorat, C. Bosetti, P. H. Brown, J. Burn, N. R. Cook, L. G. Ford, et al. 2015. "Estimates of Benefits and Harms of Prophylactic Use of Aspirin in the General Population." *Annals of Oncology* 26:47–57.
- Ford, E. S., U. A. Ajani, J. B. Croft, J. A. Critchley, D. R. Labarthe, T. E. Kottke, W. H. Giles, and S. Capewell. 2007. "Explaining the Decrease in US Deaths from Coronary Disease, 1980–2000." *New England Journal of Medicine* 356:2388–98.
- van Leeuwen, Redmer, M. Kamran Ikram, Hans Vingerling, Jacqueline C. M. Witteman, Paulus de Jong, and Albert Hofman. 2003. "Blood Pressure, Atherosclerosis, and the Incidence of Age-Related Maculopathy: The Rotterdam Study." *Investigative Ophthalmology & Visual Science* 44:3771–77.
- Wennberg, David E., F. Lee Lucas, John D. Birkmeyer, Carl E. Bredenberg, and Elliott S. Fisher. 1998. "Variation in Carotid Endarterectomy Mortality in the Medicare Population: Trial Hospitals, Volume, and Patient Characteristics." *Journal of the American Medical Association* 279:1278–81.